Lunch and Guided Laboratory Tours to Follow
For ten years, the Glioblastoma Foundation has been dedicated to improving the lives of patients and families affected by glioblastoma through research, education, advocacy, and the pursuit of targeted therapies.
As we celebrate our tenth anniversary, we look toward the future. This special symposium will showcase the Glioblastoma Foundation's vision for personalized drug development for glioblastoma — an integrated approach that brings together precision diagnosis, comprehensive genomic testing, translational research, biomarker discovery, innovative clinical trials, and the development of new therapies.
Dr. Kwatra will deliver the welcome remarks and present the Foundation's long-term vision for building the infrastructure needed to accelerate personalized medicine and develop more effective therapies.
A pioneer of personalized medicine, Dr. Snyderman will discuss how individualized health care can reshape the future of glioblastoma diagnosis, treatment, and research.
Dr. Gilbert will provide an overview of the current treatment landscape, scientific advances, and emerging opportunities that offer new hope for patients and families.
The Glioblastoma Foundation believes that personalized medicine requires more than genomic testing alone. It requires an integrated ecosystem that connects scientific discovery with patient care.
Precision molecular diagnosis through comprehensive clinical genomic profiling, so that treatment decisions begin with a complete molecular picture of the tumor.
Repurposing existing drugs through direct testing on live patient tumors.
Identifying molecular markers that predict treatment response, and new therapeutic targets.
Investigator-initiated clinical trials designed to bring novel treatment approaches to patients faster.
Following the symposium, guests are invited to join us for lunch and guided tours of Gliolab, the Glioblastoma Foundation's CLIA-certified clinical genomics laboratory.
Visitors will have the opportunity to meet members of our scientific team and learn how advanced molecular technologies are being used to support precision diagnosis for patients with glioblastoma while helping build the infrastructure for personalized drug development.
